FDA panel recommends approval for gene-altering cancer treatment

An FDA advisory panel yesterday recommended approval for Novartis‘ (NYSE:NVS) CAR-T gene therapy. If approved, it would be the first ever treatment of its kind on the market.
The panel voted unanimously, 10-0, to recommend that the FDA give its official nod. The company’s therapy genetically alters a patient’s own cells to fight acute lymphoblastic leukemia.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA panel recommends approval for gene-altering cancer treatment appeared first on MassDevice.

Source: Mass Device - July 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Oncology Regulatory/Compliance Wall Street Beat Novartis Source Type: news